Immunic Advances in Neurology: Key Conferences This April Highlighting Groundbreaking Research
Immunic to Showcase Breakthroughs in Neurology This April
Immunic, Inc. (Nasdaq: IMUX), a pioneering late-stage biotechnology firm, is set to make waves in the neurologic disease arena by participating in significant scientific and medical conferences throughout April. This involvement will underscore the company's commitment to advancing innovative therapies, particularly focusing on its lead asset, vidofludimus calcium (IMU-838).
Key Conference Highlights
1. Neuroimmunology Drug Development Summit
From April 14 to April 16, Immunic's Chief Scientific Officer, Dr. Hella Kohlhof, will present vital research at the 8th Annual Neuroimmunology Drug Development Summit in Boston. Dr. Kohlhof's presentation, titled **
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.